AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today announced two poster presentations at
the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting
being held May 31-June 4, 2019 in Chicago, Illinois.

Presentation Details

Title: Efficacy and safety of tivozanib in recurrent,
platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
First
Author:
Wendy M. Swetzig, PhD, Northwestern University Feinberg
School of Medicine
Abstract Number: 5538
Poster
Session:
Gynecologic Cancer
Poster Board: 361
Date
and Time:
Saturday, June 1, 2019, 1:15-4:15 PM CT
Location:
Hall A

Title: TIVO-3: Subgroup analysis of progression-free
survival of tivozanib compared to sorafenib in subjects with refractory
advanced renal cell carcinoma (RCC)
First Author: Camillo
Porta, MD, Associate Professor, Department of Internal Medicine,
University of Pavia and Division of Translational Oncology, IRCCS
Maugeri, Italy
Abstract Number: 4572
Poster Session: Genitourinary
(Nonprostate) Cancer
Poster Board: 398
Date and
Time:
Monday, June 3, 2019, 1:15-4:15 PM CT
Location:
Hall A

About Tivozanib (FOTIVDA®)

Tivozanib (FOTIVDA®) is an oral, once-daily, vascular
endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)
discovered by Kyowa Hakko Kirin and approved for the treatment of adult
patients with advanced renal cell carcinoma (RCC) in the European Union
plus Norway and Iceland. It is a potent, selective and long half-life
inhibitor of all three VEGF receptors and is designed to optimize VEGF
blockade while minimizing off-target toxicities, potentially resulting
in improved efficacy and minimal dose modifications.1,2 Tivozanib
has been shown to significantly reduce regulatory T-cell production in
preclinical models3 and has demonstrated synergy in
combination with nivolumab (anti PD-1) in a Phase 1/2 study in RCC.
Tivozanib has been investigated in several tumor types, including renal
cell, hepatocellular, colorectal and breast cancers. In addition, a new
formulation of tivozanib is in pre-clinical development for the
treatment of age-related macular degeneration.

About AVEO

AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a
biopharmaceutical company seeking to advance targeted medicines for
oncology and other unmet medical needs. The Company is working to
develop and commercialize its lead candidate tivozanib in North America
as a treatment for RCC. The Company has sublicensed tivozanib (FOTIVDA®)
for oncological indications in Europe and other territories outside of
North America. Tivozanib is approved in the European Union, as well as
Norway and Iceland, for the first-line treatment of adult patients with
RCC and for adult patients who are vascular endothelial growth factor
receptor and mTOR pathway inhibitor-naïve following disease progression
after one prior treatment with cytokine therapy for RCC. The Company
also has clinical collaborations to study tivozanib in combination with
immune checkpoint inhibitors in RCC and in hepatocellular carcinoma. In
addition, a new formulation of tivozanib is in pre-clinical development
for the treatment of age-related macular degeneration. As part of the
Company’s strategy, the Company has also entered into partnerships to
help fund the development and commercialization of its other product
candidates. Ficlatuzumab, a hepatocyte growth factor inhibitory
antibody, is currently being tested in several investigator sponsored
studies jointly funded by the Company and one of its development
partners for the potential treatment of head and neck squamous cell
carcinoma, acute myeloid leukemia, and pancreatic ductal adenocarcinoma.
The Company’s partner for AV-203, an anti-ErbB3 monoclonal antibody, is
planning to initiate clinical studies in China in 2019 in esophageal
squamous cell carcinoma and has committed to funding the development of
AV-203 through proof-of-concept. The Company has recently regained the
rights to AV-380, a humanized IgG1 inhibitory monoclonal antibody
targeting growth differentiation factor 15, a divergent member of the
TGF-ß family, for the potential treatment of cancer cachexia, and is
working to initiate preclinical toxicology studies in 2019 to support
the potential filing of an investigational new drug application with the
FDA. The Company is evaluating options for the development of AV-353, a
preclinical asset which targets the Notch 3 pathway.

For more information, please visit the Company’s website at www.aveooncology.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within
the meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.

References

1. Fotivda (Tivozanib) SmPC August 2017
2. Motzer RJ, Nosov D,
Eisen T, et al. J Clin Oncol 2013; 31(30): 3791-9.
3. Pawlowski N
et al. AACR 2013. Poster 3971.

Contacts

AVEO:
David Pitts, Argot Partners
(212) 600-1902